Evotec (NASDAQ:EVO) Shares Gap Up to $4.07

Evotec SE (NASDAQ:EVO) gapped up before the market opened on Thursday . The stock had previously closed at $4.07, but opened at $4.49. Evotec shares last traded at $4.46, with a volume of 150,876 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on EVO shares. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Evotec in a research report on Thursday, May 23rd. Deutsche Bank Aktiengesellschaft upgraded Evotec from a “hold” rating to a “buy” rating in a report on Friday, April 12th.

Evotec Price Performance

The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43. The business’s 50-day moving average is $5.27 and its two-hundred day moving average is $7.38.

Institutional Investors Weigh In On Evotec

A number of large investors have recently modified their holdings of EVO. Quadrant Capital Group LLC purchased a new position in Evotec in the 4th quarter worth approximately $25,000. Cetera Advisors LLC acquired a new position in shares of Evotec during the first quarter worth $188,000. Optiver Holding B.V. boosted its stake in shares of Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares during the period. Finally, Mubadala Investment Co PJSC acquired a new stake in Evotec during the 4th quarter valued at $53,931,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.